dine (a loading dose of 2 μg/kg at 10 min followed by 0.028 μg/kg/h for 48 h). Whole-brain phosphorus-31 and regional proton MRS biomarkers were assessed at baseline, 24, and 48 h after HI. At 48 h, cell death was evaluated over 7 brain regions by means of transferase-mediated d-UTP nick end labeling (TUNEL). Dexmedetomidine plasma levels were mainly within the target sedative range of 1 μg/L. In the hypothermia + dexmedetomidine group, there were 6 cardiac arrests (3 fatal) versus 2 (non-fatal) in the hypothermia + fentanyl group. The hypothermia + dexmedetomidine group required more saline ( p = 0.005) to maintain blood pressure. Thalamic and white-matter lactate/N-acetylaspartate did not differ between groups ( p = 0.66 and p = 0.21, respectively); the whole-brain nucleotide triphosphate/exchangeable phosphate pool was similar ( p = 0.73) over 48 h. Cell death (TUNEL-positive cells/mm 2 ) was higher in the hypothermia + dexmedetomidine group than in the hypothermia + fentanyl group (mean 5.1 vs. 2.3, difference 2.8 [95% CI 0.6-4.9], p = 0.036). Hypothermia + dexmedetomidine treatment was associated with adverse cardiovascular events, even Keywords Neonatal encephalopathy · Hypothermia · Dexmedetomidine · Magnetic resonance spectroscopy
Introduction
Intrapartum-related neonatal encephalopathy (NE) leads to a considerable global public health burden, resulting in 50 million disability life-adjusted years in babies who survive; in 2010 this related to 2.4% of the global burden of disease and 6.1 million years of life with disability [1, 2] . Therapeutic hypothermia (TH) has reduced the combined rate of mortality and severe disability in moderate-to-severe NE, with the number needed to treat to avoid death and/or an adverse neurodevelopmental outcome of 6 or 7 in developed countries [3] . However, despite cooling, around 50% of infants have adverse outcomes [4] . Effective and safe adjunct therapies are needed to augment hypothermic neuroprotection.
Dexmedetomidine is a highly selective α 2 -adrenoceptor agonist that confers sedative, anti-inflammatory, analgesic, sympatholytic, and organ-protective properties [5] . Pre-clinical [6] and clinical studies [7] show the importance of sedation during TH, and recent data has shown the critical importance of the sensitizing effect of perinatal inflammation and infection in both high-and low-income socio-economic groups [8] [9] [10] . There are concerns with the routine long-term use of opioids in neonates [11] . A sedative that enhances macrophage phagocytosis and bacterial clearance, minimizing inflammation-induced brain injury, but with no neurotoxicity, would be particularly helpful in these patients.
Dexmedetomidine has extensive experimental support for its neuroprotective effects by both α 2 -and non-α 2 -adrenoceptor-mediated mechanisms. Dexmedetomidine has shown neuroprotection in neonatal models of hypoxic-ischaemic brain injury [12] and anaesthetic brain injury in rodents [13] . Dexmedetomidine has a dose-dependent anti-inflammatory effect on plasma cytokine release following sepsis [14] and neuroprotective properties in sepsis-induced brain injury [15] .
Dexmedetomidine has been used as a sedative in critically ill children and neonates [16] . A dose-dependent haemodynamic response has been seen with hypotension, hypertension, and bradycardia, particularly with increasing plasma concentrations [17] [18] [19] . Dexmedetomidine effects may be opposing and depend on central and peripheral actions. Close monitoring of circulatory dynamics with dexmedetomidine has been recommended, especially with TH where there is the potential for altered pharmacokinetics (PK) and pharmacodynamics (PD) [20] . In our previous study, we investigated dexmedetomidine PK during hypothermia and rewarming to determine the safe and effective dose for use in a study of neuroprotection after hypoxia-ischaemia (HI). We found reduced dexmedetomidine clearance due to the cumulative effects of hypothermia and HI. Indeed, dexmedetomidine clearance was reduced almost 10-fold compared to adult values; PK analysis estimated that a loading dose of 2 μg/kg dexmedetomidine followed by 0.028 μg/kg/h would achieve the sedative target plasma concentration of 0.5-0.6 μg/L with hypothermia after HI [21] .
We hypothesized that hypothermia + dexmedetomidine would lead to more enhanced brain protection than hypothermia + fentanyl after global HI. Our aim was to assess whether an optimized dose of dexmedetomidine started 10 min after HI augments routine hypothermic neuroprotection in a piglet perinatal asphyxia model. This model also has strong similarities to newborn infants with NE in terms of the timing of the evolution of injury after HI [22, 23] , the pattern of injury, neuropathology, and cerebral magnetic resonance spectroscopy (MRS) biomarkers [24] . The effectiveness of dexmedetomidine protection was assessed by means of: (i) cerebral MRS biomarkers, proton ( 1 H) MRS lactate/N-acetylaspartate (Lac/NAA) [24] and phosphorus-31 ( 31 P) MRS for phosphocreatine/inorganic phosphate (PCr/Pi) and nucleotide triphosphate (NTP)/exchangeable phosphate pool (epp) [22] , and (ii) a histological assessment of cell death using transferase-mediated d-UTP nick end labeling (TUNEL) at 48 h after HI.
Material and Methods

Sample Size Calculation
Our primary outcomes were cerebral Lac/NAA and NTP/epp. Previous work with our model suggested that the change in Lac/ NAA over 48 h varied between normo-and hypothermic groups by 1.0 U, with a standard deviation of 0.65 U (log scale). Assuming a similar magnitude of additional effects for hypothermia + dexmedetomidine versus hypothermia + fentanyl following HI, and similar variability at 48 h and with 5% significance and 80% power, at least 8 subjects were required in each group based on a pairedsample t test calculation. 
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Animal Experiments and Surgical Preparation
All animal experiments were approved by the University College London ethics committee and were performed under UK Home Office Guidelines (Animals [Scientific Procedures] Act, 1986). The study complied with the ARRIVE guidelines. Twenty newborn male piglets with a birth weight of 1.6-2.1 kg and <48 h of age were anaesthetized and surgically prepared as described previously [23] . The study timeline is shown in Figure 1 .
Following clinical assessment, piglets were sedated with intramuscular midazolam (0.2 mg/kg). Whilst monitoring arterial oxygen saturation (SpO 2 ), anaesthesia was induced by the inhalation of isoflurane (4% v/v) through a face mask to facilitate tracheostomy and intubation. Throughout the surgery, isoflurane was maintained at 2.8-3% guided by peripheral oxygen saturation monitoring (Nonin Medical, Plymouth, MN, USA) and the animal's response to stimulation. Following tracheostomy, a suitable size of endotracheal tube (Smiths Medical, Ashford, Kent, UK) was fixed and the piglet was mechanically ventilated (SLE2000 Infant Ventilator, Croydon, UK). Ventilator settings were adjusted to maintain the partial pressure of oxygen (PaO 2 ) at 8-13 kPa and carbon dioxide (PaCO 2 ) at 4.5-6.5 kPa, allowing for temperature and fraction of inspired oxygen (FiO 2 ) correction of the arterial blood sample. After the airway was secured, both common carotid arteries were surgically isolated at the level of the fourth cervical vertebra, and a vascular occluder (OC2A, In Vivo Metric, Healdsburg, CA, USA) was placed on each side. After completion of the surgery, the inspired isoflurane concentration was maintained at 2% v/v.
An umbilical venous catheter was inserted for the infusion of maintenance fluids (10% dextrose, 60 mL/kg/day before the insult and 40 mL/kg/day after resuscitation), fentanyl (5 μg/kg/h) in the cooling group, and antibiotics (benzyl penicillin 50 mg/kg, every 12 h and gentamicin 4 mg/kg, once a day). An umbilical arterial catheter was inserted for invasive physiologic monitoring (SA instruments) for heart rate and mean arterial blood pressure (MABP), and blood sampling for arterial gases and electrolytes (Abbot Laboratories, UK). Hepsal (0.5 IU/mL of heparin in 0.9% saline solution) was infused at 0.3 mL/h to prevent umbilical arterial catheter blockage.
Piglets were cared for under intensive care conditions throughout the experiment. To maintain the MABP above 40 mm Hg, bolus infusions of 0.9% saline (Baxter; 10 mL/kg), dopamine (5-20 μg/kg/min), dobutamine (5-20 μg/kg/min), and adrenaline (0.1-1.5 μg/kg/min) were used as required by an NICU-trained clinician. High serum lactate was treated by optimizing oxygenation and 0.9% saline bolus infusions. Hyperkalaemia (K >7.0 mmol/L) was treated with 4 μg/kg salbutamol (10 μg/mL) over 10 min.
MRS Methods
The head was immobilized in a stereotactic frame for MRS acquisition. Piglets were positioned within the bore of 9.4-tesla Agilent MR scanners. 1 H and 31 P MRS data was acquired at baseline and at 24 and 48 h after cerebral HI. 159 31 P MRS A 7 × 5 cm elliptical transmit-receive MRS surface-coil tuned to the 31 P-resonant frequency was positioned on top of the head. 31 P MRS was acquired with 1-min resolution using non-localized, single-pulse acquisition. MRS data was analyzed using the advanced method for accurate, robust, and efficient spectral fitting (AMARES) of MRS data with use of prior knowledge [25] as implemented in the jMRUI software. Prior knowledge of NTP multiplet structure was used. NTP is predominantly ATP and the latter contributes approximately 70% of the NTP signal [26] . Thus NTP changes during this experiment predominantly reflected ATP changes. Pi was fitted using 4 separate components and PCr with a single component. The following peak area ratios were calculated: Pi/epp, PCr/epp, and NTP/epp, where epp = Pi + PCr + 2γ-NTP + β-NTP. 1 H MRS The 1 H MRS data was collected from voxels located in the dorsal right subcortical white matter at the centrum semiovale level (white matter voxel 8 × 8 × 15 mm) (deep grey-matter voxel 15 × 15 × 10 mm) 65 × 55 mm elliptical receive surface coil, a 150-mm-diameter transmit volume coil and a LASER acquisition (TR = 5,000 ms, TE = 288 ms, 128 averages). Spectra were analyzed using AMARES and the Lac/NAA peak area ratio was calculated.
Cerebral HI
The 31 P MRS data was collected at baseline, during HI, and for 1 h after the cessation of HI. HI was induced inside the MR scanner by remotely inflating the vascular occluders around both common carotid arteries, and simultaneously reducing FiO 2 to 6% (v/v). During HI, the β-NTP peak height was continuously monitored using in-house MATLAB (MathWorks) software. At the point at which β-NTP had fallen to 50% of its baseline value, FiO 2 was increased to 9%. When β-NTP fell to 40% baseline height, the inspired oxygen fraction was titrated to keep the β-NTP peak height between 30 and 40% of its original height for a period of 12.5 min. At the end of HI, the carotid arteries were de-occluded and the FiO 2 returned to 21%.
Experimental Groups
Following transient HI and after resuscitation, piglets were randomized by computer-generated randomization to: (i) hypothermia + fentanyl throughout the study ( n = 10), or (ii) hypothermia + dexmedetomidine ( n = 10). A loading dose of 2 μg/kg dexmedetomidine was started at 10 min after resuscitation and infused over 20 min, followed by a maintenance dose of 0.028 μg/kg/h for the next 48 h. Fentanyl was stopped upon starting maintenance dexmedetomidine. Blood for the dexmedetomidine PK assay was sampled at 10, 20, 40, and 60 min, and thereafter at 2, 4, 6, 12, 24, 36, and 48 h after HI. Both groups were cared for over 48 h after HI and kept hypothermic (a core temperature of 33.5 ° C) from 2 h until 26 h.
Amplitude-Integrated EEG
After surgical preparation, multi-channel, 6-lead EEG monitoring (Nicolet, CareFusion, Madison, WI, USA) was recorded at baseline and throughout the periods between MRS data acquisitions. Filtered, amplitude-integrated EEG (aEEG) recordings were classified according to the voltage criteria [27] . Grade 1 denoted a severely abnormal voltage, with a lower and upper margin of the bandwidth of <5 and <10 μV, respectively, grade 2 denoted a lower margin and upper margin of ≤ 5 and >10 μV, respectively, and grade 3 a lower and upper margin of >5 and >10 μV, respectively.
Brain Histology
At 48 h after HI, piglets were euthanized with pentobarbital, their brains were fixed by cardiac perfusion with cold 4% paraformaldehyde, and then dissected out and post-fixed at 4 ° C in 2% paraformaldehyde for 7 days. Coronal slices (5-mm-thick) of the right hemisphere, starting from the anterior to the optic chiasma, were embedded in paraffin, sectioned to 8-μm-thickness and stained with haematoxylin and eosin to validate the bregma for analysis. For each animal and brain region, TUNEL-positive nuclei were counted at 2 levels, from 7 regions (3 fields/region) by an investigator blinded to the treatment group, and the average counts/ field of view were converted into counts/mm 2 ( Fig. 2 ). To assess cell death, brain sections were stained for nuclear DNA fragmentation using histochemistry with TUNEL as previously described [28] . Briefly, TUNEL sections were pretreated in 3% hydrogen peroxide, subjected to a protease K pre-digestion (Promega, Southampton, UK), and incubated with TUNEL solution (Roche, Burgess Hill, UK). TUNEL was visualized using avidin-biotinylated horseradish complex (ABC, Vector Laboratories, Peterborough, UK) and diaminobenzidine/H 2 O 2 (DAB, Sigma, Poole, UK) enhanced with COSO 4 and NiCl 2 . TUNEL sections were dehydrated and cover-slipped with DPX (VWR Int. Ltd., Leighton Buzzard, UK).
Statistical Methods
Physiological Variables
The mean level of physiological measurements for the 2 treatment groups was compared by firstly taking the average of the results taken at baseline and T = 0, and then at 15-min intervals during the following periods: 2-3.5 h, 3.75-26 h, and 26.25-48 h for each subject. Analysis of variance (ANOVA) was then performed on the least-squares (LS) means fitting terms treatment, period, and a treatment × period interaction. The means for each period and differences in means for the 2 treatments are presented with confidence intervals (CIs) in Table 2 .
MRS
All analyses were performed using the SAS JMP ® v11.0.0 software. A statistical model was fitted to the ratios NTP/epp, PCr/Pi, and Lac/NAA. An ANOVA model was fitted and the differences in the means on the log scale for the 2 treatment groups (hypothermia + dexmedetomidine vs. hypothermia + fentanyl) were estimated from the model at each of the 3 time points with their 95% CIs. The differences in treatment group means are shown graphically using 95% least significant difference error bars. aEEG Following the baseline scoring, scores were assigned at 3, 6, 12, 24, and 36 h after HI, and group averages were compared. TUNEL An ANOVA model was fitted to the mean counts to give an estimate of the expected counts/mm 2 . The overall difference between the means for the 2 treatment groups and the treatment differences across regions are presented with 95% CIs and graphically using 95% least significant difference error bars. 160 Pharmacokinetics A 1-compartment linear disposition model was used to fit earlier data to the PK model [21] . Population parameter estimates were obtained using non-linear mixed-effects modelling (NONMEM VII, Icon Development Solutions, Elliot City, MD, USA) [29] . This model accounts for population parameter variability (between subjects) and residual variability (random effects) as well as parameter differences predicted by covariates (fixed effects). A visual predictive check (VPC) [30] , a modeling tool that estimates the concentration prediction intervals and graphically superimposes these intervals on observed concentrations after a standardized dose, was used to ascertain if our observed concentrations were predicted by the parameter estimates from that earlier study [21, 31] . Concentration prediction intervals from the earlier study were graphically superimposed on the intervals determined by the concentrations that we observed. Simulation was performed with parameter estimates from the earlier study by using 1,000 subjects with characteristics taken from the new patients. For this kind of data, where covariates such as dose, weight, and height are different for each patient, a prediction-corrected visual predictive check [32] was used; observations and simulations were multiplied by the population baseline value divided by the baseline value estimated for individuals.
Results
There were 10 animals in each group.
Baseline Physiological Data and Insult Severity
There were no intergroup differences in postnatal age, body weight, duration of HI, and insult severity as measured by acute energy depletion on 31 P MRS ( Table 1 ) . The baseline blood gas CO 2 was lower ( p = 0.033, but still within the normal range) and the blood lactate higher ( p = 0.002) in the hypothermia + dexmedetomidine group than in the hypothermia + fentanyl group ( Table 2 ) . Baseline MABP, heart rate, SpO 2 , arterial blood gas O 2 , base excess, glucose, blood pH, and core body temperature were similar in the 2 groups. The baseline O 2 was higher in the hypothermia + dexmedetomidine group but similar in the other time epochs.
Just after resuscitation, the hypothermia + fentanyl group had a lower SpO 2 than the hypothermia + dexmedetomidine group ( p = 0.044); in the time periods 2-3.5 162 and 26-48 h, the blood gas PaO 2 was higher in the hypothermia + fentanyl group than in the hypothermia + dexmedetomidine group ( p = 0.032 and p = 0.029, respectively). In the period 2-3.5 h after HI, the temperature was lower in the hypothermia + dexmedetomidine group than in the hypothermia + fentanyl group ( p = 0.027).
There was weak evidence for a lower MABP in the hypothermia + dexmedetomidine group than in the hypothermia + fentanyl group in the period 26-48 h after HI ( p = 0.071). Dex, dexmedatomidine; CL, confidence limit; SEM, standard error of the mean; SED, standard error of the difference; MABP, mean arterial blood pressure; HR, heart rate; BE, base excess; Lac, lactate; Glu, glucose; pH, blood pH; T, °C, core temperature. Significant p values are in bold type. pothermia + dexmedetomidine and hypothermia + fentanyl groups, 5/10 versus 1/10 subjects required noradrenaline, 4/10 versus 2/10 subjects required adrenaline for MABP support, 7/10 versus 3/10 subjects required adrenaline for resuscitation, 6/10 versus 2/10 subjects had a cardiac arrest, and 3/10 versus 0/10 subjects had a fatal cardiac arrest. More saline was required for BP support in the hypothermia + dexmedetomidine group than in the hypothermia + fentanyl group ( p = 0.005).
MRS Analysis
The LS means plots and 95% least significant difference bars for NTP/epp, PCr/Pi, and Lac/NAA (on log 10 scale) in the thalamus and white matter are shown in Table 4 . Least-square mean and confidence limits for the total dose throughout the study of saline, dopamine, and dobutamine treatment in the hypothermia + dexmedetomidine versus hypothermia + fentanyl (Control) groups Table 5 . There was no difference at 48 h between groups for any of the MRS peak area ratios. There was weak evidence that the NTP/epp in the brains of the hypothermia + dexmedetomidine group was lower than in the hypothermia + fentanyl group ( p = 0.05) at 24 h, but at 48 h, this difference was no longer observed.
EEG
There was no difference in mean aEEG score at any time point between the hypothermia + fentanyl and hypothermia + dexmedetomidine groups ( Fig. 4 ) .
Hypothermia + Dexmedetomidine Increased TUNEL-Positive Cell Counts
Representative photomicrographs of TUNEL staining in the putamen and periventricular white matter are The TH + Dex group showed no evidence of a difference compared to the TH + fentanyl group. TH, therapeutic hypothermia; Dex, dexmedetomidine; epp, exchangeable phosphate pool; PCr, phosphocreatine; Pi, inorganic phosphate; Lac, lactate; NAA, N-acetylaspartate. shown in Figure 5 a. A paired t test comparing the overall TUNEL count means (across all fields and subjects) of the 2 treatment groups for each of the 7 regions as well as overall was performed ( Table 6 ). There was evidence of a difference between treatment groups ( p = 0.036) ( Fig. 5 b) , with the hypothermia + dexmedetomidine group displaying more TUNEL-positive cells/mm 2 than the hypothermia + fentanyl group. The mean count for the hypothermia + dexmedetomidine group was 5.1 versus 2.3 for the hypothermia + fentanyl group (a mean difference of 2.8 [95% CI 0.6-4.9]). The regional brain counts for the 2 groups are shown in Figure 5 c.
Dexmedetomidine PK
The mean plasma concentrations of dexmedetomidine after a loading dose of 2 μg/kg over 20 min followed by an infusion of 0.028 μg/kg/h were <1 μg/L, despite the model predicting slightly higher concentrations ( Fig. 6 ). Figure 6 a shows the prediction-corrected observed concentrations. Figure 6 b shows prediction-corrected percentiles (10, 50, and 90%) for the observations (red lines with symbols) and predictions (lines) with 95% CIs for the prediction percentiles (grey-shaded areas). Graphically, the median predictions and observations lie almost on top of each other. The dexmedetomidine plasma concentrations (observations) were as predicted and were mainly within the clinical sedative range of <1 μg/L. 
Discussion
When compared to routine hypothermia + fentanyl sedation after HI, we did not observe any improvement in cerebral protection based on the MRS biomarkers Lac/ NAA and NTP/epp with hypothermia + dexmedetomidine. There was increased cell death across the combined 7 brain regions with hypothermia + dexmedetomidine compared to hypothermia + fentanyl. All piglets were anaesthetized with isoflurane, which may have exacerbated the cardiovascular effects. The hypothermia + dexmedetomidine group required more saline for BP support than the hypothermia + fentanyl group, and there were 3 fatal cardiac arrests in the hypothermia + dexmedetomidine versus none in the hypothermia + fentanyl group. These effects occurred despite dexmedetomidine plasma levels being within the target sedative range of 1 μg/L.
In preparation for this study, we had previously studied the PK of dexmedetomidine in piglets [21] ; compared with adult values, clearance was reduced almost 10-fold in the newborn piglet following HI brain injury and subsequent TH. This reduced clearance was related to the cu- mulative effects of both the hypothermia and the exposure to hypoxia. We observed that high plasma concentrations of dexmedetomidine were associated with major cardiovascular complications. From a 1-compartment model, we estimated that a bolus of 2 μg/kg dexmedetomidine over 20 min followed by an infusion of 0.028 μg/kg/h during TH would likely achieve a plasma concentration of 0.5-0.6 μg/L (the concentration associated with safe sedation in human newborns [33] ). In this study, despite achieving plasma concentrations mainly <1 μg/L with the calculated infusion rate, we saw adverse cardiovascular responses; there was no relation between the plasma concentration and adverse cardiovascular responses. The baseline physiological data showed a lower PaCO 2 and higher lactate concentration in the blood of the hypothermia + dexmedetomidine group than in the hypothermia + fentanyl group. However, all other variables were similar at baseline, and also these differences were not apparent at later time points in the study. The severity of the HI insult was similar in the 2 groups. At 2-3.5 and 26-48 h, the mean PaO 2 was lower in the hypothermia + dexmedetomidine group than in the hypothermia + fentanyl group; this may reflect the cardiovascular and haemodynamic instability observed in the hypothermia + dexmedetomidine group.
Many of the properties of dexmedetomidine, including sedation, are transduced via α 2 -adrenoceptor signaling. The α 2 -receptors are located in the blood vessels, the sympathetic terminals, and the brain, where their activation causes vasoconstriction, anxiolysis, sedation, and analgesia. Dexmedetomidine is 1,600 times more specific to α 2 -receptors than to α 1 -receptors, permitting its use for sedation without the cardiovascular side effects of α 1 -receptor activation [18] . Dexmedetomidine stands out from other sedatives, including opioids, due to its minimal respiratory depression, its anti-shivering effect, and the prevention of opioid-induced muscle rigidity [34] . The haemodynamic changes and requirement for BP support that we saw in our study can be explained by the properties of dexmedetomidine: in the central nervous system, it produces sympatholysis and lowers BP, and in the peripheral nervous system, it causes vasoconstriction which leads to an increase in BP.
A recent phase-II/III multi-center, safety, and PK study of dexmedetomidine in term and preterm infants ( ≥ 28 to ≤ 44 weeks' gestation; predominantly those intubated following surgery) suggested that dexmedetomidine is effective for sedating these neonates, is well tolerated, and is without major adverse events [35] . They observed 3 adverse events (hypotension, hypertension and agitation).
The PK profile of dexmedetomidine differed in neonates and older children, with a longer half-life and a greater area-under-the-curve drug concentration over time; this confirms our previous findings in piglets, i.e. that lower doses are required to achieve the same levels of sedation and avoid adverse effects with newborns. In other clinical studies, bradycardia, hypotension, and hypertension have been observed in children to varying degrees, depending on the plasma concentration of dexmedetomidine [33, 36, 37] . In our study, the combination of immaturity, HI, hypothermia, and concomitant use of isoflurane are likely to have increased the risk of adverse effects from dexmedetomidine despite the plasma levels of mainly <1 μg/L.
Further work is needed before our results are extrapolated to humans, as some recent studies have suggested beneficial effects with dexmedetomidine: in 102 patients receiving dexmedetomidine on the first day after cardiac surgery compared to an age-and procedure-matched cohort not receiving dexmedetomidine, the use of a dexmedetomidine infusion was associated with a decreased incidence of acute kidney injury but no change in clinical outcomes [38] . In a retrospective cohort study on infants undergoing surgical intervention for congenital heart defects requiring cardiopulmonary bypass, the use of dexmedetomidine in the operating room at the time of sternal closure was associated with a reduced need for mechanical ventilation in the immediate post-operative period. No increased adverse outcomes were reported in these infants, despite their exposure to deep hypothermic circulatory arrest and intraoperative fentanyl [39] .
There are counteracting and complex interactions between the α 2 -agonist and α 2 -adrenoreceptor subtypes which may be affected by hypothermia. The α 2 -adrenergic receptors present in the brainstem decrease BP; the activation of presynaptic α 2A -adrenoreceptors decreases sympathetic outflow and norepinephrine release, causing hypotension and bradycardia [40] [41] [42] . Post-synaptic α 2B -adrenoreceptors on vascular smooth muscle mediate vasoconstriction and are responsible for hypertension. Pre-synaptic α 2C -adrenoreceptors are also inhibitory autoreceptors with a prominent role in the peripheral autonomic system [43] ; they are sensitive to temperature and become active at temperatures <37 ° C [44] . All the piglets in our study were cooled from 2 h until 26 h after HI and the adverse cardiovascular effects (cardiac arrest) may have been due to the combination of hypothermia + dexmedetomidine. We did not assess the effect of dexmedetomidine without hypothermia, as cooling is the routine therapy for moderate-to-severe NE. Cooling has the potential to change the expression of α 2C -receptors; silent intracellular α 2C -receptors become active and translocate to the cell surface, and cause vasoconstriction following exposure to temperatures <37 ° C [44] .
TH-related bradycardia has been reported in young children following dexmedetomidine infusion [34, 45] . Furthermore, it is known that dexmedetomidine interferes with thermoregulation and itself promotes hypothermia [46, 47] . This may explain our observation of a significantly lower body temperature at 2-3.5 h in the hypothermia + dexmedetomdine group, although this was not below the target TH range. We have previously shown that the depth of hypothermia is critical for its efficacy in this model [48] .
It has been shown that anaesthesia influences the haemodynamic effects of dexmedetomidine. In anaesthetized patients with depressed sympathetic tone, dexmedetomidine increased the MABP by peripheral vasoconstriction, but in awake patients with intact tone, it decreased MABP via the centrally mediated effect of α 2 -agonists [49] . Rapid dexmedetomidine injection in a group of young children during isoflurane anaesthesia for cardiac catheterization transiently increased systolic and diastolic BP [50] . All piglets in our study were anaesthetized with isoflurane throughout the experiments. Inhaled isoflurane has been shown to reduce cardiac output and systemic vascular resistance [51] . The negative inotropic and peripheral vasodilatation effects of isoflurane are likely to augment the effects of dexmedetomidine on cardiac output, and they may have added to the adverse cardiovascular responses in the piglets receiving dexmedetomidine. Isoflurane-anaesthetized dogs and cats developed greater negative cardiovascular effects with dexmedetomidine as an adjunct compared to isoflurane-only anaesthesia [52, 53] . Dexmedetomidine reduces cardiac output, and the subsequent redistribution of blood flow limits hepatic and other non-vital organ perfusion [54] ; this, in turn, reduces the hepatic blood flow and hydroxylation and clearance [55, 56] . In our piglets, it is likely that the interaction between dexmedetomidine and isoflurane anaesthesia (the negative inotropic effect and vasodilation) are likely to have increased the depression of the sympathetic activity [57] by the variable binding to peripheral and central α 2 -adrenergic receptors [58] .
There are conflicting reports of neuroprotection and neurotoxicity with dexmedetomidine and clonidine (an α 2 -adrenoceptor agonist approximately 8 times less selective towards the α 2 -adrenoceptor than dexmedetomidine). The effect of acute (25 μg/kg) or prolonged (25 μg/ kg 3 times daily for 2 or 4 days) exposure of dexmedetomidine with TH on uninjured neonatal Lewis rats was studied [59] . Prolonged dexmedetomidine treatment in neonatal rats was not associated with abnormal brain histology (there was no increased gliosis, macrophage activation, or apoptosis in either the hypothermic or control rats). Although no adverse effects were seen, these animals were not injured, nor did they have fentanyl and isoflurane exposure. Other rodent studies have shown that dexmedetomidine protects the brain against focal [60, 61] and global [62, 63] HI by inducing anti-apoptotic effects [64, 65] , or via α 2 -adrenergic and imidazole 1 receptors [12] . In the developing mouse brain, dose-dependent neuroprotection with dexmedetomidine and clonidine was found [66] . Some studies, however, have shown that dexmedetomidine and clonidine induce cerebral hypoperfusion and neurotoxicity in small-animal stroke models [67] . Dean et al. [68] showed a complex dose-dependent response to clonidine with low doses, but not high doses, being neuroprotective after hypoxic brain injury in preterm fetal sheep. We observed the combination of hypothermia + dexmedetomidine to be neurotoxic with more TUNEL-positive cells (5.1 vs. 2.3/mm 2 mean counts across the brain) than with hypothermia + fentanyl. One mechanism that could have led to this was the reduction in cerebral blood flow by vasoconstriction in the pial arteries and veins [69] . Studies on rats and dogs demonstrated that dexmedetomidine dose-dependently caused vasoconstriction in the pial arteries mediated either by direct action on α 2 -adrenoreceptors, or on the small cerebral arteries distal to the circle of Willis [70] . Other studies have shown that systemic dexmedetomidine indirectly induces cerebral vasoconstriction by reducing cerebral oxygen consumption [69] .
The reasons for these conflicting reports may be related to the differences in species, models, the maturity of the brain, the dose and timing of the drugs, and the integrity of the autonomic system. Different expressions of α-adrenoreceptor subtypes in cerebral arteries in humans, monkeys, and dogs can lead to different responses to noradrenaline, α 2 -agonists, and antagonists. An agedependent change in the expression and binding capacity of α 2 -receptors in postnatal life occurs in human and rat brains, and this may affect the sensitivity of newborns to dexmedetomidine [71] .
Our study suggests that caution is needed when considering the use of dexmedetomidine with hypothermia in the newborn after HI. We saw no improvement in cerebral energetics on MRS when we examined hypothermia + dexmedetomidine versus hypothermia + fentanyl. There was evidence of neurotoxicity with an increased number of TUNEL-positive cells across the brains treated with hypothermia + dexmedetomidine compared to those treated with hypothermia + fentanyl. We saw some expected haemodynamic effects of dexmedetomidine; adverse effects and cardiac arrest may relate to interactions between reduced clearance in an immature animal, concomitant anaesthesia exacerbating the cardiovascular effects of dexmedetomidine, and the effects of hypothermia on temperature-sensitive α 2C -receptors. Reduced cerebral perfusion induced by dexmedetomidine is likely to have contributed to the neurotoxicity.
